PND56 BUDGET IMPACT ANALYSIS OF INCLUSION IN THE PUBLIC FINANCING OCRELIZUMAB THERAPY FOR PRIMARY-PROGREDIENT AND HIGHLY ACTIVE REMITTING FORMS OF MULTIPLE SCELEROSIS IN THE RUSSIAN FEDERATION

Abstract

Authors

M. Holownia-Voloskova T. Ermolaeva D. Klabukova A. Fisun K. Poliakova M. Grinin M. Davydovskaya